Over-the-Counter Availability of Fluticasone

OTC Availability and Regulatory Status

The European Position Paper on Rhinosinusitis and Nasal Polyps recommends that intranasal medications containing fluticasone are classified as over-the-counter (OTC) in most developed countries, and can be dispensed with pharmacists' advice 1, 2, 3
Fluticasone propionate and fluticasone furoate are available OTC in most developed countries, allowing patients to purchase these intranasal corticosteroids without a prescription after consultation with a pharmacist 1, 2, 3

Fluticasone is suitable for self-management of chronic rhinosinusitis symptoms and acute post-viral rhinosinusitis when symptom reduction is needed 1, 2, 3
OTC intranasal corticosteroids are the mainstay treatment for chronic rhinosinusitis and require long-term adherence for optimal benefit 1, 2, 3

Fluticasone propionate and fluticasone furoate are generally preferred among intranasal corticosteroids because they have negligible bioavailability and less potential to cause systemic side effects 1, 2, 3
These formulations require only once-daily dosing, which improves patient adherence 1, 2, 3

Some OTC medications may only be dispensed after an assessment of the patient by a pharmacist and provision of patient education 1, 2, 3
The community pharmacist acts as a bridge between primary care and specialist care in integrated patient-centered management 1, 2, 3

Do not assume OTC availability means no professional guidance is needed - pharmacist consultation ensures appropriate use and proper administration technique 1, 2, 3
Patients should be aware of both common side effects (nasal irritation, epistaxis) and serious side effects that require reporting to healthcare providers 1, 2, 3

The American Academy of Otolaryngology recommends that fluticasone furoate and fluticasone propionate are not directly interchangeable due to distinct molecules with different potencies and dosing regimens, making direct substitution inappropriate without dose adjustment 4, 5

Meta-analyses show no significant differences in symptom improvement between fluticasone propionate, mometasone furoate, and budesonide when used at appropriate doses, indicating all are clinically effective despite molecular differences 4, 5
Both agents have negligible bioavailability and minimal potential for systemic side effects, making them preferred choices among intranasal corticosteroids for safety reasons 6

Long-term use up to 52 weeks has been demonstrated as safe for both agents, with no evidence of nasal mucosal atrophy on biopsy after 1-5 years of continuous therapy 4
If a patient is stable and well-controlled on one formulation, there is no clinical reason to switch unless cost, availability, or patient preference dictates the change 4, 5
Product differentiation between the two involves factors such as cost, OTC status, and sensory issues like aroma and taste, which can affect patient preferences rather than clinical efficacy 6